← boardnext 2028-07
ABSI
Absci Pty Ltd.distress 5/10 · elevated risk$8.02-3%today-31% from 52w high
Lead: Androgenetic Alopecia (AGA)
Revenue
pre-revenue
Liquidity
$131M
Runway
1.3 yrs
Shares 1y
+4%
Price & events
+153.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-2.6%
1W
+8.2%
1M
+101.9%
3M
+175.4%
6M
+127.7%
1Y
+80.1%
2Y
-65.0%
5Y
-62.9%
All
Overview
- Market Cap
- $1.25B
- Enterprise Value
- $1.24B
- Volume
- 216.80K
- 52 Week Range
- $2.30 – $11.62
- Total Shares
- 155.91M
- Float Shares
- 148.72M
- Short %
- 26.61%
- % Held by Insiders
- 12.04%
- % Held by Institutions
- 73.01%
- RVOL
- 0.03x
- Beta
- 2.33
Pipeline stages · 1 programs
ABS-201 IV Single Dose, ABS-201 SC Multiple Doses
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-07 Estimated 50% readout ~2028-08-15 | Phase 1/2 | ABS-201 IV Single Dose, ABS-201 SC Multiple Doses | Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female | — | recruiting |
Catalyst news & presentations · 4
- 2026-08-11earningsEarningsEarnings releaseyahoo
- June 24, 2026readoutPhase 1ABS-201 · Interim Phase 1 data from the HEADLINE trialSEC 8-K
- January 14, 2026conferencedata presentationsecondaryBusiness update at 44th J.P. Morgan Healthcare ConferenceSEC 8-K
- January 15, 2025conferencedata presentationsecondaryBusiness update presentation at 43rd Annual J.P. Morgan Healthcare Conference.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $14 (+72% upside) · 9 analysts
- 2026-07-02Truist SecuritiesBuy
- 2026-06-25HC Wainwright & Co.Buy
- 2026-06-24BTIGBuy
- 2026-06-24NeedhamBuy
- 2026-06-15GuggenheimBuy
- 2026-06-04Leerink PartnersOutperform
Competitors — Androgenetic Alopecia (AGA)
- none identified
Recent news
- 2026-07-14Absci sets 4:30 p.m. ET webcast for its Aug. 11 Q2 update - Stock Titan
- 2026-07-13Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know - Yahoo Finance
- 2026-07-06H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
- 2026-07-06Absci director Mary T Szela buys $148,866 in stock - Investing.com
- 2026-07-06Form 4 Absci Corp For: 6 July By Investing.com - Investing.com Canada
- 2026-06-26Is Absci (ABSI) Overvalued Following Phase 1 Progress And A $100 Million Raise? - simplywall.st
- 2026-06-26Absci (NASDAQ: ABSI) CEO has 59,896 shares withheld for RSU tax obligation - Stock Titan
- 2026-06-26Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.